- Motley Fool•17 hours ago
The FDA has approved Dupixent for moderate to severe eczema, and it has accepted the company's resubmission of sarilumab for rheumatoid arthritis. These drugs could give shares the shot in the arm they need.
- Thomson Reuters StreetEvents•yesterday
Q1 2017 Sanofi SA Earnings Call
- The Wall Street Journal•2 days ago
French drugmaker Sanofi said 1Q net profit jumped to about $6.2 billion, boosted by the sale of its animal-health business. To revive growth, Sanofi has boosted its research and is seeking to acquire an ...
SAN.PA : Summary for SANOFI - Yahoo Finance
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||86.17 - 88.00|
|52 Week Range||62.50 - 88.00|
|PE Ratio (TTM)||23.85|
|Dividend & Yield||3.35 (3.60%)|
|1y Target Est||N/A|